Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
B.-C. Liao
ResearcherPublications, citations & collaboration network
B.-C. Liao is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 3 works, 6 citations, an h-index of 2 and an i10-index of 0.
3
Works
6
Citations
2
h-index
0
i10-index
IDs:OpenAlex
How has B.-C. Liao's publication output changed over time?
ScholarIQpublication output · 2022–2025
Output grew0% over the shown period — from 1 works in 2022 to 1 in 2025.
1
1
1
202220242025
What are the most-cited papers on B.-C. Liao?
ScholarIQmost cited works
P4.07D.04 Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC
Jang‐Ming Lee, B.-C. Liao, Jonathan Spicer, T. Newsom-Davis, RosalineChung-Yee Hui, Yiquan Xu, A. Song, Ayman Samkari, M. Hochmair
Journal of Thoracic Oncology. 20244 Citations
EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
B.-C. Liao, C.-Y. Yang, T.-H. Tsai, W.-Y. Liao, K.-Y. Chen, C.-C. Ho, J.-Y. Shih, C.-J. Yu, J.C.-H. Yang
Journal of Thoracic Oncology. 20222 CitationsOPEN ACCESS
Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study
Chieh‐Lin Jerry Teng, Yu-Min Liao, B.-C. Liao
Blood. 20250 CitationsOPEN ACCESS
Related on ScholarIQ
Taichung Veterans General Hospital
Institution
P4.07D.04 Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC
Paper
EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Paper
Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study
Paper
Colorectal Cancer Treatments and Studies
Topic
Cancer Immunotherapy and Biomarkers
Topic